The global autism spectrum disorder treatment market size is expected to reach USD 3.95 billion by 2033, registering a CAGR of 6.92% from 2025 to 2033, according to a new report by Grand View Research, Inc. Many of the experimental autism spectrum disorder (ASD) drugs in the academic studies and pharma pipeline are assessing important theories about how the genetic fingerprint and brain contribute to the development of autism. Some of the pipeline drugs include AB-2004 & AB-2004 PTR by Axial Therapeutics, Inc., Zygel by Zynerba Pharmaceuticals, Inc., and INP105 (Olanzapine) by Impel Pharmaceuticals Inc.
In July 2022, Impel Pharmaceuticals Inc. initiated the first patient dose in phase 2a study evaluating INP-105 to treat acute agitation in adolescents with autism spectrum disorder (ASD). The company uses its Precision Olfactory Delivery (POD) technology to deliver medicine to the upper nasal part and increase the absorption of the drug, without the need for injection. Thus, technological advancement in drug delivery is anticipated to drive the market.
In May 2020, HARMAN International and F. Hoffmann-La Roche Ltd. entered into a global partnership to develop a digital therapeutic platform for individuals with ASD. Under this partnership, Harman and Samsung combined their extensive technology with F. Hoffmann-La Roche Ltd.’s leadership in neuroscience to develop innovative therapies for the treatment of ASD.
Rising awareness and funding for research and development of autism spectrum disorder are expected to positively contribute to the growth of the market. For instance, the Sapienza Università di Roma every year celebrates the 2nd of April as ‘World Autism Awareness Day’ with an aim to increase awareness about the disease and its treatment benefits among physicians and patients. Furthermore, in November 2022, the Defiance County Board of Developmental Disabilities/Good Samaritan School and the Andrew Jimenez Autism Fund received a donation of USD 1000 from Buckeye Roofing and Exteriors owner to support the efforts to raise awareness about ASD, subsequently creating an opportunity for the market growth.
Request a free sample copy or view report summary: Autism Spectrum Disorder Treatment Market Report
By treatment type, the antipsychotic drugs segment dominated the market with the largest revenue share of 40.95% in 2024
Based on application, the autistic disorder segment dominated the market with the largest revenue share of 54.23% in 2024
The retail pharmacy segment dominated the market with the largest revenue share of 63.98% in 2024
North America held the largest share of the autism spectrum disorder treatment market in 2024, accounting for 42.73% of global revenue, due to its advanced diagnostic framework and strong clinical infrastructure.
Grand View Research has segmented the global autism spectrum disorder treatment market on the basis of on treatment type, application, distribution channel, and region:
Autism Spectrum Disorder Treatment Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
Antipsychotic Drugs
Selective Serotonin Reuptake Inhibitors
Stimulants
Sleep Medications
Others
Autism Spectrum Disorder Treatment Application Outlook (Revenue, USD Million, 2021 - 2033)
Autistic Disorder
Asperger Syndrome
Pervasive Developmental Disorder
Others
Autism Spectrum Disorder Treatment Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Autism Spectrum Disorder Treatment Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Autism Spectrum Disorder Treatment Market
Curemark LLC
Bristol-Myers Squibb Company
Merck & Co., Inc.
Novartis AG
Eli Lilly and Company
Pfizer Inc.
Johnson & Johnson Services Inc.
Otsuka Pharmaceutical Co., Ltd.
Yamo Pharmaceuticals
F.Hoffmann-La Roche Ltd.
Axial Therapeutics Inc.
"The quality of research they have done for us has been excellent..."